System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof Sophie Georgin-Lavialle is an expert in Rheumatology at Tenon Hospital (France). As of October 2026, ScienceLeadR ranks Sophie Georgin-Lavialle in the top 1% of experts worldwide for Coronavirus Infections, Pneumonia and Epidemiologic Studies. Sophie Georgin-Lavialle has authored 530 publications, the most recent in 2026, and is an investigator in 21 clinical trials, 11 of them ongoing. SLR score: 2,089 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Sophie Georgin-Lavialle Tenon Hospital France
2 089 ScienceLeadR Reputation 2089

Unlock

Register Login
Network Map

Rheumatology

Subspecialties: Internal Medicine - Hematology - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2004 - 2026
Source: PubMed

Centre de Recherche Saint-Antoine

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 530

Citations

Citations: 10 062 1st author: 60 Last author: 172 Unique author: 2

Main journals

Rev Med Interne 139
Ann Rheum Dis 36
Eur J Intern Med 17
Rheumatology (Oxford) 16
Joint Bone Spine 13

Best Journals

Lancet Respir Med 2
N Engl J Med 2
JAMA Intern Med 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Reported Clinical Practice in Still Disease in France in 2024: A Descriptive Analysis and Comparison With Current Different National Guidelines.
PMID 42758915 — glucocorticoids, rheumatologists, phenotype, rheumatic diseases, physicians, therapeutics		J Clin Rheumatol20260
Extending the ATP9A-Related Phenotypic Spectrum: Indication of Schizophrenia Susceptibility.
PMID 42757772 — genes, mental disorders, neurodevelopmental disorders, introns, schizophrenia, psychotic disorders, neurodevelopment		Am J Med Genet B Neuropsychiatr Genet20260
AA amyloidosis in the four historical monogenic autoinflammatory diseases: Clinical burden and insights from a retrospective referral-centre study.
PMID 42706496 — internal medicine, amyloidosis, diagnosis		J Intern Med20260
[AA Challenge: An interactive French-language educational program on the causes of AA amyloidosis - Analysis of 2,597 responses to 12 clinical quizzes].
PMID 42704357 — kidney diseases, language, education, medical, arthritis, amyloidosis, physicians, diagnosis		Nephrol Ther20260
Rescue of Eosinophilic Cardiac Tamponade by Anakinra in a Pregnant Woman With Familial Mediterranean Fever.
PMID 42643765 — pregnant women, familial mediterranean fever, adrenal cortex hormones, eosinophils, cardiac tamponade, pericarditis, hypereosinophilic syndrome, myocarditis, interleukin-1, eosinophilia		Case Reports Immunol20260

Clinical Studies 21

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 5

By phase:

N/A 10
Phase 2 7
Phase 3 2
Phase 1 1
Phase 2/Phase 3 1

By status:

Completed 7
Recruiting 7
Not yet recruiting 3
Active not recruiting 2
Unknown 1
Withdrawn 1

By type:

Interventional 13
Observational 8

By Monocentric/Multicentric:

monocentric 13
multicentric2to4 1
multicentric5to9 2
multicentricup10 5

Main Topics

Cohort/Consortium Investigators 5

Ongoing Clinical Trials

11 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A study to assess the effectiveness and safety of pacritinib in patients with VEXAS syndrome (PAXIS)
2024-516347-41-00 — safety		Phase 2Recruiting2025
Host microbiota Interactions in Auto inflammatory Diseases
NCT07718555 — dysbiosis, host microbial interactions, microbiota		N/ARecruiting2026
A study to test how well BI 3000202 is tolerated by people with type 1 interferonopathies
2024-514942-35-00		Phase 1Active not recruiting2025
An open label phase II trial to evaluate the clinical efficacy safety and tolerability of MAS825 in pediatric and adult participants with Still s disease
2024-520208-25-00 — safety		Phase 2Recruiting2026
National Cohort of Patients With SITRAME Syndrome
NCT07168746 — rare diseases		N/ANot yet recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS